ArticleJournal of Taibah University Medical Sciences2025
Impact of CYP2A6 genetic polymorphism on letrozole efficacy in Iraqi women with polycystic ovary syndrome.
Article in Journal of Taibah University Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer.Journal of Taibah University Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated the effects of a genetic polymorphism in CYP2A6 (CYP2A6∗2, 1799T>A) on the therapeutic response to letrozole in Iraqi women with polycystic ovarian syndrome (PCOS)-induced infertility. Methods: A prospective, single-center, randomized, controlled pragmatic clinical trial was conducted in 94 Iraqi women with PCOS-induced infertility. The ovulation response to letrozole (2.5 mg/day for 5 days) was assessed via ultrasound (follicle size ≥18 mm) and hormonal assays (follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin, testosterone, and anti-Müllerian hormone). Genotyping of CYP2A6∗2 (1799T>A, rs1801272) was performed using allele-specific PCR on blood-derived DNA, and the distribution of wild-type (AA), heterozygous (AT), and mutant (TT) alleles was recorded. The association between genotype and letrozole efficacy, including follicle size, endometrial thickness, sex hormone levels, and pregnancy incidence, was also evaluated. Results: The wild-type allele (AA) of the CYP2A6∗2 gene (1799A>T, rs1801272) was widely distributed in approximately 51 (54.26 %) women with PCOS. Heterozygous alleles (AT) and mutant alleles (TT) were present in 2 (2.13 %) and 41 (43.61 %) women with PCOS, respectively. There was no notable difference between infertile women who did or did not respond to letrozole and those who carried different genotypes (wild-type AA, heterozygous AT, and mutant TT) of CYP2A6 (1799T>A) regarding sex hormones, follicle size, endometrial thickness, or incidence of gestation ( Conclusion: The CYP2A62 (1799T>A) genetic variant was not associated with letrozole efficacy or resistance in Iraqi women with PCOS, suggesting that this polymorphism does not significantly influence therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.